The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists. GLP-1 ...

Evoke Pharma (NASDAQ:EVOK) shares rocketed 90% early Monday on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in diabetic patients using GLP-1 drugs. The study ...

The real-world retrospective study evaluated the impact of GIMOTI (metoclopramide nasal spray) in patients with diabetic gastroparesis (DGP) who were concurrently using GLP-1 receptor agonists.

Fares Qeadan, PhD, from the Parkinson School of Health Sciences and Public Health at Loyola University Chicago, and colleagues evaluated the strength of the GIP/GLP-1 RA and substance use-outcome ...

Between 2022 and 2023, prescriptions for GLP-1 drugs soared 132.6% while bariatric surgery rates fell 25.6%, according to a new study from researchers at Boston-based Harvard Medical School and ...

Researchers from Mass General Brigham and collaborators found that use of GLP-1 drugs to treat obesity more than doubled from 2022 to 2023 while rates of surgery dropped by one quarter. Key ...

Eli Lilly’s performance is riding on the success of GLP-1 weight loss and Alzheimer’s treatments. It is especially true for its GLP-1 drugs, which have led to massive gains, with more to come.

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds. Prescriptions of this GLP-1 class ...

Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds By Ernie Mundell HealthDay Reporter FRIDAY, Oct. 25, 2024 (HealthDay News) -- As the popularity of GLP-1 meds like Wegovy and ...

But in the last few years, with the approval of GLP-1 drugs like Wegovy and Zepbound, more and more people are opting for obesity medicines over gold-standard surgical treatments. “On a ...

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...